Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
This observational study focuses on understanding the natural progression of Angelman syndrome AS in children and adults who have a confirmed genetic diagnosis of AS. It aims to track how developmental skills such as communication, motor abilities, and adaptive behaviors change over one year, and to identify specific brain activity or sleep patterns linked to symptom changes. The study includes both children and adults, with a particular emphasis on childhood and adolescence. Participants will be grouped into cohorts based on age, including children aged 1 to 17 years, a subset of preadolescents aged 1 to 12 years, and a small group of adults aged 18 years and older. Over one year, participants will attend up to five study visits three in-person visits at weeks 0, 26, and 52, and two virtual visits at weeks 13 and 39. During these visits, participants will undergo assessments such as developmental tests, behavior questionnaires, and sleep evaluations, including wearing a sleep-monitoring device at home and having brain activity recorded via electroencephalograms EEGs. Participants and their caregivers will help complete questionnaires and tests about development, behaviors, and sleep. The research team will measure changes in cognitive, communication, and motor skills using standardized scales like the Bayley Scale of Infant Development. Sleep and brain activity data will be collected through actigraphy and EEGs to analyze neurophysiological changes. The total study duration for participants is approximately one year, with ongoing monitoring of symptoms and clinical features to better understand AS and support future trials.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNZ-2591 compared to a placebo in children aged 3 to 12 years with Phelan-McDermid Syndrome. This Phase 3, randomized, double-blind, placebo-controlled study aims to understand how NNZ-2591 may impact symptoms related to this genetic condition. After consent, participants enter a 4-week screening period to determine eligibility and baseline symptom levels. Eligible children are then randomly assigned to receive either NNZ-2591 or a matching placebo, both taken orally twice daily, for 13 weeks. Following treatment, there is a 2-week safety follow-up to monitor any side effects. Throughout the study, participants undergo various assessments including symptom severity scales and caregiver impressions to measure changes. Researchers evaluate the primary outcomes at week 13 using specific tools for symptom change and communication abilities. The total duration of participation is approximately 17 to 19 weeks, including screening, treatment, and follow-up.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and effectiveness of NNZ-2591 in children with Phelan-McDermid Syndrome in this Phase 3 open-label extension study. The trial focuses on pediatric participants who have previously taken part in related studies and aims to better understand the impact of this treatment over an extended period. Participants who qualify will take NNZ-2591 orally twice daily for a year during the Treatment Period. After completing this 52-week phase, there is a 2-week safety follow-up period to monitor any lasting effects or side effects. The study is designed to assess how well participants tolerate the treatment and to observe any changes in their symptoms. During the study, participants will undergo assessments to confirm eligibility, establish baseline health and symptom severity, and monitor safety through adverse event tracking, ECG, vital signs, and laboratory tests. Researchers will also evaluate treatment effects using specific behavioral and severity scales at 3 and 12 months. The total time commitment for each participant is up to 56 weeks, including treatment and follow-up.
Actively Recruiting
Researchers are evaluating buspirone, an anxiety medication, to see if it is effective, safe, and tolerable for children and adolescents aged 7 to 17 years who have autism spectrum disorder and experience anxiety. This study is a phase 4, randomized controlled trial comparing buspirone to a placebo in autistic youth with moderate to severe anxiety. Participants must meet specific diagnostic criteria and be able to swallow the medication. Participants will be randomly assigned to receive either buspirone or a matching placebo for 16 weeks. The buspirone dose will be adjusted during the first 12 weeks to find a stable dose, which will then be maintained for the last 4 weeks. Standardized anxiety assessments will be done at weeks 4, 8, 12, and 16, and any side effects will be reviewed at each visit. During the study, participants will attend regular visits for dose adjustments, anxiety evaluations, and safety monitoring. Researchers will measure changes in anxiety using tools like the Pediatric Anxiety Rating Scale and Clinical Global Impression scales. The study is sponsored by Massachusetts General Hospital and aims to understand how buspirone affects anxiety symptoms in autistic youth over the 16-week treatment period.
Actively Recruiting
Healthy Volunteer
Researchers are creating a network of hospitals, labs, academic institutions, and healthcare organizations to provide annotated biospecimens for various types of medical research and education. These biospecimens will be used for biomarker discovery, diagnostic test development, therapeutics research, and training of researchers and physicians. Participants may be healthy or have medical conditions relevant to ongoing research needs. The study involves collecting remnant specimens originally obtained for clinical testing or specimens collected specifically for research, including biofluids, tissues, and cells. Participants may be identified during clinical care or recruited through outreach programs. Biospecimens may be distributed to various research entities such as academic institutions and companies for diverse research uses, including genetic testing, cell line development, and long-term storage. Participants may undergo minimal risk screening activities and provide biospecimens as needed. The research team will collect data over a 10-year period to support novel research uses. Biospecimens may be used for multiple research and educational purposes, including training laboratory technicians and physicians. The study includes participants aged 1 to 89 years and involves assessment of health status through medical record reviews and clinical exams when blood collection is needed.
Actively Recruiting
Healthy Volunteer
Researchers are conducting an observational study to gather health data, lifestyle details, biological samples, and participant feedback. The goal is to connect people with specific health profiles to scientific researchers looking for new diagnostics and treatments for various conditions like lupus, celiac, and dermatologic diseases. This study aims to speed up medical discovery by linking patient participation with research efforts. Participants in this study will not receive any treatments, as it is non-interventional and observational only. People may be healthy or have certain health conditions. They will be invited to join specific projects based on the needs of each research study. The study collects de-identified health data and biospecimens over time to support medical research. During the study, participants will provide samples and information through surveys, interviews, and other minimal risk activities. Researchers will monitor biological markers over a period of 10 years to identify important health indicators. Participants need to comply with study procedures and remain available throughout the study, which runs until 2036. The study focuses on safety and privacy while advancing medical knowledge.
Actively Recruiting
The Gaucher Outcomes Survey GOS is a long-term, international, observational registry for patients with Gaucher Disease, regardless of their treatment status or type of treatment received. This study aims to better understand the natural course of Gaucher Disease and to evaluate the safety and long-term effects of treatments like velaglucerase alfa in real-world clinical practice. The registry collects data to support evidence-based management of patients over time. Participants in this registry do not receive experimental treatments as part of the study. Instead, they continue their usual care as determined by their treating physicians. The registry includes patients receiving velaglucerase alfa or other Gaucher Disease-specific therapies, capturing clinical assessments and treatment information over many years. During the study, patients undergo regular clinical evaluations, and data on their health status, treatment safety, and disease progression are collected. Key outcomes measured include adverse events, infusion-related reactions, blood counts, and changes in liver, spleen, and bone mineral density. The study plans to follow participants for up to 20 years to gather comprehensive long-term data.
Actively Recruiting
Researchers are evaluating the use of heart rate variability biofeedback HRVB, a breathing-based technique, to reduce anxiety in autistic youth aged 12 to 17 years. This study focuses on second-generation wearable HRVB devices that provide both scheduled training sessions and in-the-moment practice prompts. The goal is to assess how acceptable and feasible this approach is, as well as to explore its initial effectiveness in treating anxiety in this population. Participants will use the Lief Smart Patch, a wearable device with an embedded ECG monitor and accelerometer, connected to a smartphone app that guides HRVB practice. Over an 8-week period, they will practice HRVB twice daily for 5 minutes at times they choose and respond to prompts for brief, approximately 2-minute sessions when the device detects signs of stress. They are asked to complete at least 5 minutes of HRVB daily, combining prompted and self-initiated practice. During the study, participants will complete assessments of anxiety using the Pediatric Anxiety Rating Scale and other clinical measures at the start, midpoint, and end of the trial. Usability of the app and the feasibility of the device will also be evaluated. The study is fully remote and open-label, lasting 8 weeks, with participants and their guardians completing questionnaires and other evaluations throughout the period.
Actively Recruiting
Healthy Volunteer
Researchers are studying how drugs given to children and young adults by their healthcare providers behave in their bodies. The goal is to find the safest and most effective doses for these understudied drugs used as part of standard medical care. This observational study includes participants up to 20 years old and focuses on various conditions including COVID-19, heart failure, asthma, and others. The study collects bodily fluid samples, such as whole blood and effluent, from children and young adults who are prescribed drugs of interest as part of their routine care or who are SARS-CoV-2 positive. The drugs are not given as part of the study but are prescribed by the participants healthcare provider. Data collection lasts up to 90 days after consent, extended to 210 days for participants with Down Syndrome at designated sites. Participants contribute by allowing sample collection and providing health information during the study period. Researchers measure drug clearance, volume of distribution, elimination rate, half-life, absorption rate, concentration levels, and timing to reach maximum concentration. Monitoring focuses on pharmacokinetics and pharmacodynamics to understand how these drugs act in children. The study is sponsored by Duke University and runs until December 2026.
1-10 of 11
1